Search

Search Results

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2470

  PDF: 1613

  HTML: 664

• IRON METABOLISM IN THALASSEMIA AND SICKLE CELL DISEASE

  Raffaella Mariani, Paola Trombini, Matteo Pozzi, Alberto Piperno

  e2009006

  2009-10-27

  1663

  PDF: 659

  HTML: 43931

• MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY

  Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

  e2017021

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.021

  3502

  PDF: 1321

  HTML: 1952

  Fig.1: 224

  Fig. 2: 221

• CARDIAC FUNCTION AND IRON CHELATION IN THALASSEMIA MAJOR AND INTERMEDIA: A REVIEW OF THE UNDERLYING PATHOPHYSIOLOGY AND APPROACH TO CHELATION MANAGEMENT

  Athanasios Aessopos, Vasilios Berdoukas

  e2009002

  2009-07-18

  1622

  PDF: 489

  HTML: 1492

• A Young Adult with Unintentional Acute Parenteral Iron intoxication Treated with Oral Chelation: The Use of Liver Ferriscan.

  Vincenzo De Sanctis

  e2017008

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.008

  3171

  PDF: 1038

  HTML: 1659

• DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA

  Ali Taher

  e2018066

  2018-11-01

  https://doi.org/10.4084/mjhid.2018.066

  3045

  PDF: 1610

  HTML: 280

• JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia

  Phakatip Sinlapamongkolkul, Pacharapan Surapolchai, Vip Viprakasit

  e2023056

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.056

  2788

  PDF: 633

  Suppl. Files: 294

  HTML: 212

• THE ICET-A RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF DISTURBANCES OF GLUCOSE HOMEOSTASIS IN THALASSEMIA MAJOR PATIENTS

  Vincenzo De Sanctis

  e2016058

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.058

  4277

  PDF: 1235

  HTML: 1255

• IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES

  Paolo Cianciulli

  e2009034

  1306

  PDF: 631

  HTML: 2325

• TRANSIENT ELASTOGRAPHY (TE) IS A USEFUL TOOL FOR ASSESSING THE RESPONSE OF LIVER IRON CHELATION IN SICKLE CELL DISEASE PATIENTS

  SOPHIA DELICOU

  e2018049

  2018-09-01

  https://doi.org/10.4084/mjhid.2018.049

  1604

  PDF: 844

  HTML: 208

• THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

  adel abd elhaleim hagag

  e2013065

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.065

  2766

  PDF: 848

  HTML: 14998

  Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 330

• LIVER IRON CONTENT (LIC) IN ADULTS WITH NON-TRANSFUSION DEPENDENT SICKLE CELL DISEASE (NT-SCD). CORRELATION WITH SERUM FERRITIN AND LIVER ENZYMES CONCENTRATIONS

  Vincenzo De Sanctis

  e2017037

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.037

  3977

  PDF: 999

  HTML: 1178

• GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis , Salvatore Di Maio, Christos Kattamis

  e2023006

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.006

  3995

  PDF: 1136

  HTML: 463

• SALIVA IRON AND FERRITIN LEVELS IN PATIENTS WITH THALASSEMIA AND IRON DEFICIENCY ANEMIA

  Duran Canatan, Sevgi Kosaci Akdeniz

  e2012051

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.051

  3012

  PDF: 1501

  HTML: 10917

• ASSOCİATİON BETWEEN IRON OVERLOAD AND GLUCOSE METABOLİSM İN CHİLDREN AND YOUTH WİTH TRANSFUSİON-DEPENDENT BETA THALASSEMİA: THE ROLE OF CHELATİON THERAPY

  Deniz Guven, Dr. İncefidan, Dr. Kazanci, Dr. Ozlem Kara

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.017

  705

  PDF: 606

  HTML: 86

• ACQUIRED HYPOGONADOTROPIC HYPOGONADISM (AHH) IN THALASSAEMIA MAJOR PATIENTS: AN UNDERDIAGNOSED CONDITION?

  Vincenzo De Sanctis

  e2016001

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.001

  5241

  PDF: 1323

  HTML: 3611

• ECONOMIC EVALUATION OF CHELATION REGIMENS FOR ?--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW

  Jialian Li

  e2019036

  2019-06-24

  https://doi.org/10.4084/mjhid.2019.036

  2043

  PDF: 1473

  HTML: 235

• CLINICAL AND BIOCHEMICAL DATA OF ADULT THALASSEMIA MAJOR PATIENTS (TM) WITH MULTIPLE ENDOCRINE COMPLICATIONS (MEC) VERSUS TM PATIENTS WITH NORMAL ENDOCRINE FUNCTIONS: A RETROSPECTIVE LONG-TERM STUDY (40 YEARS) IN A TERTIARY CARE CENTER IN ITALY

  Vincenzo De Sanctis, Heba Elsedfy

  e2016022

  2016-04-12

  https://doi.org/10.4084/mjhid.2016.022

  4051

  PDF: 1047

  HTML: 3521

• THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS

  Gehan Lotfy Abdel Hakeem, hoda Abdel kereem Abdel Samei, Ashraf mohamed El Shereif, Ahlam mohamed ismail

  e2015023

  2015-02-17

  https://doi.org/10.4084/mjhid.2015.023

  2216

  PDF: 1002

  HTML: 3033

  Untitled: 228

• LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY

  Ashraf Tawfik Soliman, Mohamed Yassin, Fawzia AlYafei, Lolwa Al-Naimi, Noora Almarri, Aml Sabt, Vincenzo De Sanctis

  e2014025

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.025

  2303

  PDF: 2180

  HTML: 2461

• JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED ?- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES

  Vincenzo De Sanctis

  e2018064

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.064

  2709

  PDF: 1227

  HTML: 288

• SEVERE LIVER IRON CONCENTRATIONS (LIC) IN 24 PATIENTS WITH ?-THALASSEMIA MAJOR: CORRELATIONS WITH SERUM FERRITIN, LIVER ENZYMES AND ENDOCRINE COMPLICATIONS

  Vincenzo De Sanctis

  e2018062

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.062

  2734

  PDF: 1414

  HTML: 330

• A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT

  Vincenzo De Sanctis, Salvatore Di Maio

  e2021040

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.040

  1582

  PDF: 520

  HTML: 213

• The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR ?-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE

  Jialian Li

  e2020029

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.029

  1875

  PDF: 987

  HTML: 304

• GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS

  Naouel GUIRAT

  e2018031

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.031

  3351

  PDF: 1045

  HTML: 445

  TABLE: 200

  FIGURES: 268

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2184

  PDF: 1176

  HTML: 2014

• THALASSAEMIA INTERMEDIA : AN UPDATE

  Ali Taher, Khaled M. Musallam, Maria Domenica Cappellini

  e2009004

  2009-08-17

  1091

  PDF: 451

  HTML: 9457

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2354

  PDF: 965

  HTML: 386

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4324

  PDF: 1544

  HTML: 462

• THALASSAEMIA AND ABERRATIONS OF GROWTH AND PUBERTY

  Andreas Kyriakou, Nicos Skordis

  e2009003

  2009-07-28

  1180

  PDF: 471

  HTML: 3258

• A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.

  SALVATORE DI MAIO, VINCENZO DE SANCTIS, PIERLUIGI MARZUILLO, CHRISTOS KATTAMIS, SHAHINA DAAR, MEHERAN KARIMI, SAKI FOROUGH, ATANAS BANKEV, VALERIA KALEVA, SOTEROULA CHRISTOU, CARMELO FORTUGNO, POLYXENI DELAPORTA, ASHRAF T SOLIMAN , PLOUTARCHOS TZOULIS

  e2023058

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.058

  824

  PDF: 546

  HTML: 123

• THE DIAGNOSTIC VALUE OF PULSED WAVE TISSUE DOPPLER IMAGING IN ASYMPTOMATIC BETA- THALASSEMIA MAJOR CHILDREN AND YOUNG ADULTS ; RELATION TO CHEMICAL BIOMARKERS OF LEFT VENTRICULAR FUNCTION AND IRON OVERLOAD .

  Seham Ragab

  e2015051

  2015-08-24

  https://doi.org/10.4084/mjhid.2015.051

  1427

  PDF: 891

  HTML: 1397

  Untitled: 196

• THE FREQUENCY OF ADRENAL INSUFFICIENCY IN ADOLESCENTS AND YOUNG ADULTS WITH THALASSEMIA MAJOR VERSUS THALASSEMIA INTERMEDIA IN IRAN

  Sara Matin, Masoud Ghanei Jahromi, Zohreh Karemizadeh, Sezaneh Haghpanah, Vincenzo De Sanctis, Ashraf Soliman, Mehran Karimi

  e2015005

  2014-08-28

  https://doi.org/10.4084/mjhid.2015.005

  2234

  PDF: 1090

  HTML: 9584

• HEALTH-RELATED QUALITY OF LIFE IN THAI CHILDREN WITH THALASSEMIA AS EVALUATED BY PEDSQL AND EQ-5D-Y: A SINGLE CENTER EXPERIENCE

  Pacharapan Surapolchai, Phakatip Sinlapamongkolkul

  e2020036

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.036

  1572

  PDF: 1166

  HTML: 342

• FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia

  Vincenzo De Sanctis, Forough Saki, Mehran Karimi, Mohammad Faranoush, Ihab Elhakim, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis

  e2025072

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.072

  723

  PDF: 268

  Html: 36

• THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA  in TDT

  Vincenzo De Sanctis, Shahina Daar, Ploutarchos Tzoulis, Ashraf Soliman, Ihab Elhakim , Mohammad Faranoush, Christos Kattamis

  e2026055

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.056

  144

  PDF: 122

  HTML: 32

• GLUCOSE METABOLISM AND INSULIN RESPONSE TO ORAL GLUCOSE TOLERANCE TEST (OGTT) IN PREPUBERTAL PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA (TDT): A LONG-TERM RETROSPECTIVE ANALYSIS Long-term retrospective analysis of glucose homeostasis in children with transfusion dependent β-thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Ploutarchos Tzoulis, Shahina Daar, Salvatore Di Maio, Bernadette Fiscina, Christos Kattamis

  e2021051

  2021-08-28

  https://doi.org/10.4084/MJHID.2021.051

  1798

  PDF: 572

  HTML: 195

• Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients

  Christos KATTAMIS, Myrto Skafida, Christalena Sofocleous, Antonis Kattamis

  e2019064

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.064

  1274

  PDF: 980

  HTML: 326

• BETA THALASSEMIA MAJOR IN A DEVELOPING COUNTRY: EPIDEMIOLOGICAL, CLINICAL AND EVOLUTIONARY ASPECT

  Mohamed Bejaoui, Naouel Guirat

  e2013002

  2013-01-01

  https://doi.org/10.4084/mjhid.2013.002

  1650

  PDF: 916

  HTML: 2517

• INFECTIONS IN THALASSEMIA AND HEMOGLOBINOPATHIES

  Bianca Maria Ricerca, Arturo Di Girolamo, Deborah Rund

  e2009028

  2009-12-28

  1237

  PDF: 632

  HTML: 4429

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  2021

  PDF: 1024

  HTML: 736

• STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .

  Seham Ragab, Manal A. Safan, Eman A. Badr

  e2015019

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.019

  2250

  PDF: 1185

  HTML: 2599

  Study of serum haptoglobin level in thalassemia: 369

  Figures: 196

• FIRST-PHASE INSULIN RESPONSE (FPIR) TO INTRAVENOUS GLUCOSE TOLERANCE TEST (IVGTT), INSULIN SENSITIVITY AND LONG-TERM FOLLOW-UP IN TRANSFUSION-DEPENDENT BETA-THALASSEMIA (TDT) NORMOGLYCEMIC PATIENTS WITH REDUCED INSULIN SECRETION TO ORAL GLUCOSE TOLERANCE TEST: A PILOT STUDY. The function of the endocrine pancreas in transfusion-dependent ?-thalassemia

  Vincenzo De Sanctis

  e2021021

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.021

  7470

  PDF: 584

  HTML: 283

• LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING

  Jassada Buaboonnam, Chayamon Takpradit, Vip Viprakasit, Nattee Narkbunnam, Nassawee Vathana, Kamon Phuakpet, Kleebsabai Sanpakit, Bunchoo Pongtanakul

  e2021065

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.065

  1201

  PDF: 444

  HTML: 173

• DOES INSULIN LIKE GROWTH FACTOR-1 (IGF-1) DEFICIENCY HAVE A “PROTECTIVE” ROLE IN THE DEVELOPMENT OF DIABETIC RETINOPATHY IN THALASSEMIA MAJOR PATIENTS?

  Vincenzo De Sanctis

  e2015038

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.038

  2010

  PDF: 947

  HTML: 5094

• REVIEW AND RECOMMENDATIONS ON MANAGEMENT OF ADULT FEMALE THALASSEMIA PATIE?TS WITH HYPOGONADISM BASED ON LITERATURE REVIEW AND EXPERIENCE OF ICET-A NETWORK SPECIALISTS

  Vincenzo De Sanctis

  e2017001

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.001

  6182

  PDF: 1449

  HTML: 1975

• INSULIN-LIKE GROWTH FACTOR-1 (IGF-1): DEMOGRAPHIC, CLINICAL AND LABORATORY DATA IN 120 CONSECUTIVE ADULT PATIENTS WITH THALASSAEMIA MAJOR

  V. De Sanctis

  e2014.074

  2014-11-01

  https://doi.org/10.4084/mjhid.2014.074

  2288

  PDF: 964

  HTML: 26952

• POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia

  Vincenzo De Sanctis, Mohammad Faranoush, Efthymia Vlachaki, Theodora- Maria Venou, Ashraf T Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025069

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.069

  539

  PDF: 259

  HTML: 47

• COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis, Christos Kattamis

  e2025050

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.050

  765

  PDF: 620

  HTML: 120

• A MULTICENTER ICET-A SURVEY ON ADHERENCE TO ANNUAL ORAL GLUCOSE TOLERANCE TEST (OGTT) SCREENING IN TRANSFUSION-DEPENDENT THALASSEMIA (TDT) PATIENTS - THE EXPERT CLINICIANS’ OPINION ON FACTORS INFLUENCING THE ADHERENCE AND ON ALTERNATIVE STRATEGIES FOR ADHERENCE OPTIMIZATION Survey on adherence to annual OGTT in thalassemia

  Vincenzo De Sanctis

  e2025008

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.008

  2965

  PDF: 1364

  HTML: 164